RNS Number : 6301F Stifel Nicolaus Europe Limited 05 March 2024 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Name
RNS Number : 5092F Unicorn Asset Management Limited 04 March 2024 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of
RNS Number : 4140F Renalytix PLC 04 March 2024 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
RNS Number : 3507F Renalytix PLC 01 March 2024 The following amendment has been made to the ' Grant of Share Options ' announcement released on 23 November 2023 at 07:00 under RNS No 3917U . The sentence " All the Share Options granted one twelfth of the Share Options vest 3 months from the
RNS Number : 9346E Renalytix PLC 29 February 2024 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO. Renalytix plc ("Renalytix" or the "Company")
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second
RNS Number : 2070D Renalytix PLC 15 February 2024 Renalytix plc ("Renalytix" or the "Company") Half Year Report LONDON and SALT LAKE CITY , February 15, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February
RNS Number : 6963C Renalytix PLC 09 February 2024 Renalytix plc ("Renalytix" or the "Company") Renalytix to Participate in the BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference LONDON and SALT LAKE CITY , February 9, 2024 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX)
RNS Number : 5654C Renalytix PLC 09 February 2024 Renalytix plc ("Renalytix" or the "Company") Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd LONDON and SALT LAKE CITY , February 9, 2024 - Renalytix plc (NASDAQ:
